Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00630721

Enrollment

Registered

2008-03-07

Start date

2007-09-30

Completion date

2011-03-15

Last updated

2018-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the expression of SOCS3 in DCs.

Interventions

OTHERIFNbeta-1b

no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Confirmed diagnosis of MS * Age 18-60 years, inclusive * Expanded disability status of 0-6.5 * Give written informed consent prior to any testing under this protocol

Design outcomes

Primary

Measure	Time frame
Determine the effect of IFN-B-1b-induced SOCS3 upregulation in DCs' on their maturation and the capacity to present	2 years

Secondary

Measure	Time frame
Characterize the effect of IFN-1b-induced SOCS3 expression in DCs on Th1/Th2 cell differentiation and T-cell cytokine transcription.	2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026